Invesco S&P International Developed ESG Index ETF News - IICE.F

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371...

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits...

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique...

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies OSE Immunotherapeutics...

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the...

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the...

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen...

OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale

OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Invesco S&P International Developed ESG Index ETF (IICE.F)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

IICE.F News

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Informations relatives au nombre total de droits de vote et d’actions composant le capital

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse

OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale

IICE.F Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Invesco S&P International Developed ESG Index ETF (IICE.F) News

Invesco S&P International Developed ESG Index ETF (IICE.F)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

IICE.F News

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Informations relatives au nombre total de droits de vote et d’actions composant le capital

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse

OSE Immuno et le Centre Hospitalier Universitaire de Nantes présentent une analyse positive de l’essai clinique de Phase 1/2 évaluant l’immunothérapie FR104/VEL-101 en transplantation rénale

IICE.F Discussion

Your Recent History